VERTEX PHARMACEUTICALS INC / MA
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Ticker / security symbols
- VRTX [1]
- Listing exchanges
- Nasdaq [1]
- SEC industry
- Pharmaceutical Preparations [1]
- Business sectors
- biotechnology industry; health care industry; pharmaceutical industry [2]
- Company / filing name
- VERTEX PHARMACEUTICALS INC / MA [1]
- Headquarters location
- Boston [2]
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210 [1]
- Founded
- 1989 [2]
- Incorporation jurisdiction
- Massachusetts, United States [1]
- Leadership in background record
- Reshma Kewalramani [2]
- Official website
- www.vrtx.com ↗ [2]
- Annual revenue
- USD 8,930,700,000 · reported year 2022 [2]
- Fiscal year end
- December 31 (SEC record) [1]
- ISIN (reported securities)
- US92532F1003 [2]
- CIK
- 0000875320 [1]
- SIC code
- 2834 [1]
- Country in background record
- United States [2]
Company positioning and business
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England. [3]
Background text: Wikipedia contributors, Vertex Pharmaceuticals. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Management and corporate governance
The Wikidata background record identifies Reshma Kewalramani in the chief-executive role. This background entry is not an official confirmation of the current board or executive roster. [2]
Understanding company scale
Annual revenue: USD 8,930,700,000 · reported year 2022. [2]
Financial year, securities and disclosures
The SEC submissions record gives VERTEX PHARMACEUTICALS INC / MA a fiscal year end of 1231 (MMDD). Individual filings below identify their own reporting period; the filing date is the publication event, not the financial year end. [1]
Listed securities: VRTX (Nasdaq). Multiple symbols may represent different share classes or securities of the same registrant. [4]
History and key events
Financial results and regulatory disclosures
Annual, quarterly and current reports from the collected SEC record. Insider Forms 4 and 144 are excluded. This is a selected list, not a live filing feed.
Source-verified relationships
Companies in the same industry
Comparison candidates share the SEC SIC classification 2834. This does not imply ownership, partnership or trading relationships.
Related entities and concepts
Frequently asked questions
When was VERTEX PHARMACEUTICALS INC / MA founded?
Founded: 1989. The linked source provides the background record. [2]
Where is the headquarters of VERTEX PHARMACEUTICALS INC / MA?
Headquarters location: Boston. The linked source provides the background record. [2]
Which business sectors are recorded for VERTEX PHARMACEUTICALS INC / MA?
Business sectors: biotechnology industry; health care industry; pharmaceutical industry. The linked source provides the background record. [2]
VERTEX PHARMACEUTICALS INC / MA relationship map
Select a node to inspect its relationship and source.
2 verified direct relationships. Industry peers are not relationship edges.
Sources and review dates
- SEC — VERTEX PHARMACEUTICALS INC / MA filing identity and securities ↗
- Wikidata — company background record (CC0) ↗
- Wikipedia contributors — Vertex Pharmaceuticals (CC BY-SA 4.0) ↗
- SEC securities directory ↗
- Company chronology / filing ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.